CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,712 enrolled
Drug / intervention
Ivermectin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02509481
NCT02509481Phase 3Completed
CompareCT.gov

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

Colorado State University·interventional·Posted Jul 28, 2015·Updated Jan 4, 2019

In Brief

A Phase 3 clinical trial evaluating Ivermectin and Albendazole for Malaria and Lymphatic Filariasis. Completed, enrolled 2,712 participants across 2 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in treated village children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria, Lymphatic Filariasis
CountriesBurkina Faso, United States
CollaboratorsInstitut de Recherche en Sciences de la Sante, Burkina Faso, Centre Muraz, Ministère de la Santé du Burkina Faso

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 28, 2015
Enrollment StartJun 1, 2015
Primary CompletionNov 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.9 years ago

Interventions

Ivermectindrug

Albendazoledrug